Vedanta Biosciences

Vedanta Bio guts out microbiome trial win to keep up with field, get BARDA cash

Vedanta Biosciences is developing its microbiome therapy with support from the Biomedical Advanced Research and Development Authority. Under terms of that contract, the positive Phase 2 results in preventing recurrent C. diff infection trigger a $23.8 million payment.

By Frank Vinluan

BioPharma, Startups

Vedanta Biosciences raises $27M in Series C round

The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.

By Alaric DeArment

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.